Ad is loading...
FTYPX
Price
$21.95
Change
+$0.12 (+0.55%)
Updated
Nov 18 closing price
JHRTX
Price
$12.50
Change
+$0.06 (+0.48%)
Updated
Nov 18 closing price
Ad is loading...

FTYPX vs JHRTX

Header iconFTYPX vs JHRTX Comparison
Open Charts FTYPX vs JHRTXBanner chart's image
Fidelity Freedom Index 2055 Premier
Price$21.95
Change+$0.12 (+0.55%)
VolumeN/A
CapitalizationN/A
JHancock Multimanager 2055 Lifetime I
Price$12.50
Change+$0.06 (+0.48%)
VolumeN/A
CapitalizationN/A
FTYPX vs JHRTX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FTYPX vs. JHRTX commentary
Nov 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTYPX is a Hold and JHRTX is a Hold.

FUNDAMENTALS
Fundamentals
FTYPX has more cash in the bank: 14.3B vs. JHRTX (426M). FTYPX pays higher dividends than JHRTX: FTYPX (1.86) vs JHRTX (1.69). FTYPX was incepted earlier than JHRTX: FTYPX (4 years) vs JHRTX (10 years). JHRTX is a more actively managed with annual turnover of: 16.00 vs. FTYPX (11.00). JHRTX has a lower initial minimum investment than FTYPX: JHRTX (250000) vs FTYPX (2000000000). JHRTX (23.23) and FTYPX (22.56) have marching annual gain over last year.
FTYPXJHRTXFTYPX / JHRTX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence4 years10 years-
Gain YTD14.42116.04590%
Front LoadN/AN/A-
Min. Initial Investment2000000000250000800,000%
Min. Initial Investment IRAN/AN/A-
Net Assets14.3B426M3,357%
Annual Yield % from dividends1.861.69110%
Returns for 1 year22.5623.2397%
Returns for 3 years11.43-12.47-92%
Returns for 5 yearsN/A16.88-
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MGRM2.050.04
+1.99%
Monogram Orthopaedics
ENSG143.49-2.19
-1.50%
Ensign Group (The)
AG6.34-0.11
-1.63%
FIRST MAJESTIC SILVER Corp
NOW1011.39-28.41
-2.73%
SERVICENOW
RVNC4.17-0.14
-3.25%
Revance Therapeutics